Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-09
2006-05-09
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S303000, C514S299000, C514S217070, C514S217040, C514S259500, C514S249000, C514S253040, C514S233200, C514S218000, C540S572000, C540S597000, C544S127000, C544S362000, C544S284000, C544S353000, C546S121000, C546S120000, C546S112000
Reexamination Certificate
active
07041675
ABSTRACT:
The invention relates to compounds of the formula Iand the tautomeric forms, possible enantiomeric and diasteromeric forms thereof, and prodrugs thereof, and use thereof as PARP inhibitors.
REFERENCES:
patent: 4096145 (1978-06-01), Schefczik
patent: 620141 (1962-10-01), None
patent: 2025427 (1971-12-01), None
patent: WO 97/04771 (1997-02-01), None
patent: WO 99/64572 (1999-12-01), None
patent: 85/1335 (1985-02-01), None
Zhang J, (1999) Emerging Drugs: The Prospect for improved Medicines. Ashley Publications Ltd. pp. 209-221.
Zhang J and Li JH. (2000) Cell Death, Szabo C (ed.) CRC Press, Boca, Raton. pp. 279-304).
J. Reisch et al., J. Heterocycl. Chem. 1990, 27, 287-289.
V. Burkart et al., Nature Med. 1999, 5, 314-319.
S. Cuzzocrea et al., Eur. J. Pharmacol. 1998, 342, 67-76.
S. Cuzzocrea et al., Br. J. Pharmacol. 1997, 121, 1065-1074.
G. Chen et al., Cancer Chemo. Pharmacol. 1988 22, 303-307.
W. Ehrlich et al., Rheumatol. Int. 1995, 15, 171-172.
K. Ikai et al., J. Histochem. Cytochem. 1983, 31, 1261-1264.
S. Shall, Adv. Radiat. Biol. 1984, 11, 1-69.
M.S. Satoh et al., Nature 1992, 356, 356-358.
H. Kroger et al., Inflammation 1996, 20, 203-215.
C. Thiemermann et al., Proc. Natl. Acad. Sci. USA 1997, 94, 679-683.
D. Weltin et al., Int. J. Immunopharmacol. 1995, 17, 265-271.
C. Szabo et al., Proc. Natl. Acad. Sci. USA 1998, 95, 3867-3872.
O.K. Kim et al., Bioorg. Med Chem Lett. 1997, 7, 2753-2758.
Buu-Hoi et al., Bull. Soc. Chim Fr. 1961, 1344.
Y. Abe et al., J. Med. Chem. 1998, 41, 564-578.
L. Fisher et al., J. Med. Chem. 1972, 15, 982-985.
Teulade et al., Eur. J. Med. Chem. Chim. Therap. 1979, 13, 271-276.
Grandel Roland
Hoeger Thomas
Kock Michael
Lubisch Wilfried
Mueller Reinhold
Abbott & GmbH & Co. KG
Huang Evelyn Mei
Wood Phillips Katz Clark & Mortimer
LandOfFree
Heterocyclic compounds and their use as PARP inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds and their use as PARP inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds and their use as PARP inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3572669